Anaplastic lymphoma kinase (ALK) inhibitors
- Name
- Anaplastic lymphoma kinase (ALK) inhibitors
- Accession Number
- DBCAT005745
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Crizotinib A receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. Ceritinib An antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib. Alectinib A kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. Lorlatinib An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. Brigatinib An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. - Drugs & Drug Targets